The Use of Uncooked Sweet Manioc Starch to Treat Hepatic Glycogen Storage Diseases
A Novel Approach to Treatment of Hepatic Glycogen Storage Diseases: a Study Based on the Use of Uncooked Sweet Manioc Starch
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
RS
-
Porto Alegre, RS, Brazil, 90035007
- Ida Vanessa D Schwartz
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients with a confirmed molecular diagnosis of glycogen storage disease type Ia who are already on uncooked cornstarch therapy
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Cornstarch
Ingestion of cornstarch, the standard treatment for hepatic Glycogen Storage Diseases.
|
100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
|
|
Experimental: Sweet manioc starch
Ingestion of sweet manioc starch, the starch in study.
|
100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of normoglycemia
Time Frame: up to 10 hours
|
To verify the normoglycemia will be accessed glucose level.
The glucose dosage will be performed by hexokinase enzyme assay.
Peripheral blood samples will be collected to determine the baseline value and every hour.
|
up to 10 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose levels
Time Frame: up to 10 hours
|
The glucose dosage will be performed by hexokinase enzyme assay.
Peripheral blood samples will be collected to determine the baseline value and every hour.
|
up to 10 hours
|
|
Lactate levels
Time Frame: up to 10 hours
|
The lactase dosage will be performed by colorimetric (Lactate → Pyruvate).
Peripheral blood samples will be collected to determine the baseline value and every hour.
|
up to 10 hours
|
|
Insulin levels
Time Frame: up to 10 hours
|
The insulin dosage will be performed by microparticle chemiluminescent immunoassay.
Peripheral blood samples will be collected to determine the baseline value and every hour.
|
up to 10 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ida D Schwartz, Dr, Hospital de Clinicas de Porto Alegre
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 160056
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.